Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Kura Oncology (KURA – Research Report). The associated price target remains the same with $40.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Kura Oncology’s promising developments. The company’s recent submission of the New Drug Application (NDA) for ziftomenib, a potential first-in-class menin inhibitor for relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation, is a significant milestone. This submission, backed by successful Phase 2 clinical trial results, positions Kura for potential FDA approval by the end of 2025.
Additionally, Kura’s strategic expansion into multiple clinical trials and its commitment to advancing its pipeline assets, such as tipifarnib and KO-2806, further strengthen its market position. The company’s efforts in exploring new indications, including gastrointestinal stromal tumors (GIST) and diabetes, demonstrate its innovative approach and potential for growth. These factors collectively suggest that Kura Oncology is well-positioned for future success, justifying the Buy rating.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.